Glaxo Operations UK Limited (manufacturer of unpackaged products)
UkraineAll drugs from this manufacturer
-
The drug is prescribed to adults for the treatment of unresectable or metastatic melanoma (provided the BRAF V600 mutation is present), as well as for adjuvant therapy of stage III melanoma and the treatment of advanced non-small cell lung cancer (provided the BRAF V600 mutation is present).
Dosage form: capsules, hard
Active substance Dosage dabrafenib 50 mg ATC: L01EC02
-
The drug is indicated for adults for the treatment of unresectable or metastatic melanoma (provided the BRAF V600 mutation is present), as well as for adjuvant therapy of stage III melanoma and the treatment of advanced non-small cell lung cancer (provided the BRAF V600 mutation is present).
Dosage form: capsules, hard
Active substance Dosage dabrafenib 75 mg ATC: L01EC02
-
The drug is used for the treatment of locally advanced and/or metastatic renal cell carcinoma, as well as for the treatment of patients with advanced soft tissue sarcoma who have previously undergone chemotherapy (with the exception of certain tumor types, such as liposarcoma or gastrointestinal stromal tumor).
Dosage form: tablets, film-coated
Active substance Dosage pazopanib 400 mg ATC: L01EX03
-
The drug is prescribed for the treatment of advanced and/or metastatic renal cell carcinoma, as well as for the treatment of patients with advanced soft tissue sarcoma who have previously received chemotherapy (except for patients with gastrointestinal stromal tumor or liposarcoma).
Dosage form: tablets, film-coated
Active substance Dosage pazopanib 200 mg ATC: L01EX03